These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12777330)

  • 21. [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol].
    Hayashi T; Hirano T; Shiobara T; Suguro T; Adachi M
    Rinsho Byori; 2006 Jun; 54(6):569-75. PubMed ID: 16872005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
    Grundy SM
    Circulation; 2002 Nov; 106(20):2526-9. PubMed ID: 12427645
    [No Abstract]   [Full Text] [Related]  

  • 25. Hyperapobetalipoproteinaemia: an emerging risk factor for atherosclerosis.
    Thompson GR; Trayner IA; Allaway SL; Robinson D; Ritchie CD
    Monogr Atheroscler; 1986; 14():129-31. PubMed ID: 3736551
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment.
    Vaverkova H; Frohlich J; Jackuliakova D; Novotny D
    Clin Biochem; 2005 Jun; 38(6):509-13. PubMed ID: 15885228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein A1 and B.
    Sniderman AD; Marcovina SM
    Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of apoE polymorphism with lipoprotein(a), apoA, apoB and lipid levels in atherosclerotic infarct.
    Tascilar N; Dursun A; Ankarali H; Mungan G; Sumbuloglu V; Ekem S; Bozdogan S; Baris S; Aciman E; Cabuk F
    J Neurol Sci; 2009 Feb; 277(1-2):17-21. PubMed ID: 18945448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis].
    Cabezas Castro M; Liem A
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1445-8. PubMed ID: 12908345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.
    St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
    Am J Cardiol; 2006 Apr; 97(7):997-1001. PubMed ID: 16563904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoproteins as markers and managers of coronary risk.
    Chan DC; Watts GF
    QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of lipid and lipoprotein profiles in risk assessment and therapy.
    Ballantyne CM; Hoogeveen RC
    Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The cholesterol contained in low-density lipoproteins or apolipoprotein B in the prediction of cardiovascular risk?].
    Vella Ramírez JC
    Rev Sanid Hig Publica (Madr); 1992; 66(5-6):251-5. PubMed ID: 1366222
    [No Abstract]   [Full Text] [Related]  

  • 38. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins.
    Berg AL; Rafnsson AT; Johannsson M; Dallongeville J; Arnadottir M
    Metabolism; 2006 Aug; 55(8):1083-7. PubMed ID: 16839845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fasting insulin and apolipoprotein B levels and low density lipoprotein particle size as risk factors for ischemic heart disease.
    Moore M
    J Insur Med; 1998; 30(2):111-2. PubMed ID: 10339292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.